SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors

by NASDAQ Market News July 14, 2020

NASDAQ Market News
Click here to email author

XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke

PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine

Ads